Breaking Reporters Denied White House Access Following Trump Ban Announcement New Research Links Ancient Tooth Grooves to Habitual Betel Nut Use Study Quantifies Extreme Heat’s Impact on India’s Informal Female Workers Storm Damage Threatens Archaeological Dig Site in Quinhagak, Alaska Russia Holds Parliamentary Elections in Illegally Annexed Ukrainian Regions

Saturday September 19, 2026

Section

Press Releases

Press Release

Stäubli Expands BosCon Portfolio with Permanent Protective Caps and Panel Receptacles for Enhanced Protection and Performance

Stäubli Electrical Connectors · Sep 14

Press Release

GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF

GENFIT S.A. · Sep 14

Press Release

KFSH Riyadh Records Zero High-Risk Findings Across Nearly 1,800 Measures in JCI Reaccreditation

King Faisal Specialist Hospital & Research Centre · Sep 14

Press Release

Identity in the Wilderness Explores Faith, Healing, and Christ-Centered Identity in Seasons of Suffering

Written By: EIN Presswire · Sep 14

Press Release

The Land Of Balance Turns Young Love Into An Adventure Between Darkness And Light

Written By: EIN Presswire · Sep 14

Press Release

Nicholas Abaza Named to Htown Best as a Top Probate Lawyer in Houston

Nick Abaza Law · Sep 14

Press Release

Smile Makeover Market Growth Rate Expected To Reach 8.4% CAGR By 2030

Written By: EIN Presswire · Sep 14

Press Release

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Business Wire · Sep 14

Press Release

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Business Wire · Sep 14

Press Release

Mitsubishi Electric’s New Plate Heat Exchanger Delivers 3x Conventional Heat Transfer Performance

Business Wire · Sep 14

Press Release

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Business Wire · Sep 14

Press Release

Home equity reaches a record $18 trillion among US mortgage holders. Here is where it runs deepest

Bill Lyons for Griffin Funding · Sep 14

Press Release

Wealthbox Brings Advisor CRM Data to “Claude for Financial Advisors”

Wealthbox · Sep 14

← Previous 1 … 766 767 768 … 832 Next →